SIREN : 843756685
PROPHARMSERV is a French company founded 7 years ago, specialized in the sector Activités des sociétés holding. Based in GREASQUE (13850), this company of category PME shows in 2024 a revenue of 195 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 195 340 € | 236 072 € | 195 516 € | 88 161 € | 63 676 € | 69 888 € |
| Net income | 255 327 € | 29 919 € | 68 982 € | 17 673 € | 28 937 € | 30 133 € |
| EBITDA | -34 976 € | 34 771 € | 64 075 € | 24 560 € | 38 221 € | 37 488 € |
| Net margin | 130.7% | 12.7% | 35.3% | 20.0% | 45.4% | 43.1% |
In 2024, PROPHARMSERV achieves revenue of 195 k€. Over the period 2019-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +22.8%. Significant drop of -17% vs 2023. After deducting consumption (574 €), gross margin stands at 195 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -35 k€, representing -17.9% of revenue. Warning negative scissor effect: despite revenue change (-17%), EBITDA varies by -201%, reducing margin by 32.6 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 255 k€, i.e. 130.7% of revenue. This profit can be retained or distributed to shareholders.
195 340 €
194 766 €
-34 976 €
-39 712 €
255 327 €
-17.9%
The debt ratio (= Financial debt / Equity x 100) stands at 29%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 17%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.4 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 134.8% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
28.592%
17.29%
134.75%
0.407
48.8%
In 2024, the debt ratio of PROPHARMSERV (28.59) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of PROPHARMSERV (17.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of PROPHARMSERV (0.41) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 290.55. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
290.549
-6.762
In 2024, the liquidity ratio of PROPHARMSERV (290.55) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of PROPHARMSERV (-6.8x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 5 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 3 days. The company must finance 2 days of gap between collections and payments. WCR is negative (-214 days): operations structurally generate cash. Notable WCR improvement over the period (-333%), freeing up cash.
-116 368 €
5 j
3 j
0 j
-214 j
Based on 54 transactions of similar company sales
in 2024,
the value of PROPHARMSERV is estimated at
218 113 €
(range 138 028€ - 844 795€).
The price/revenue ratio is 0.59x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PROPHARMSERV with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of PROPHARMSERV in 2024 is 195 k€.
Yes, PROPHARMSERV generated a net profit of 255 k€ in 2024.
The headquarters of PROPHARMSERV is located in GREASQUE (13850), in the department Bouches-du-Rhone.
The tax return of PROPHARMSERV is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PROPHARMSERV operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.